19 November 2020

Dr. Christelle Haziza discusses the future of our Disease Risk Reduction Studies.

"I can say that I strongly believe based on scientific evidence that the product has some big potential to reduce the risk of harm."

Dr. Christelle Haziza, Director Clinical Science and Biostatistics

Below is the transcript of the video:

We add another kind of study because it's one thing to show reduced exposure to toxicants, but then the second question was: what is happening at the biological level? What is the impact on inflammation? On oxidative stress? Blood flow? Coagulation? All these kinds of biological effect which are known to be damaged by smoking.

We use also biomarker to understand a little bit the lipid metabolism. Is there an improvement in lipid metabolism? Is there a reduction in inflammation? And we were also able to demonstrate that among different biomarkers which are covering different biological pathways, we demonstrated that again we had an improvement in all these biological pathways when switching to the product when you are a smoker initially and similarly to when you stop smoking,* which was really promising and the first step to show the likelihood of reduction of risk and harm.

Before putting our product on the market, we want to fully understand the safety. This is one of the benefits also with this kind of clinical study you will understand the safety profile, just to make sure that the safety is okay before putting this product on the market and to get sufficient scientific evidence on your product.

We have more than 10 million [users] of heat-not-burn tobacco product at the moment on the market and they report to have some benefit. What do I mean by benefit? As an example, they report that they have an improvement in exercise capacity, ability to breathe, or their skin - the quality of the skin is getting better. So, the next step definitely would be to validate these questions about this item that the consumers have reported from a scientific point of view through clinic studies.

I think overall, and I'm talking on my personal view here and not necessarily on behalf of Philip Morris, but because I'm leading all the clinical studies and I have been behind all the clinical studies since more than 12 years at Philip Morris so meaning that I have seen all the result. I can say that I strongly believe based on scientific evidence that the product has some big potential to reduce the risk of harm.

* In a 6-month study the improvement in biomarkers in those who switched moved in the direction of when you stop smoking.



Sharon Carty Page Overview 2

Watch Sharon Carty explain the importance of disease risk reduction studies

Dr.HazizaOGImage Our studies

Watch Dr. Haziza talk about the different disease risk reduction studies

Sharon Carty for Page Overview

Watch Sharon Carty outline the planning that goes with disease risk reduction studies